Evidence map›Paper›PMID 40408246›Full record

ArticleCell reports2025

Regulatory network analysis of Dclk1 gene expression reveals a tuft cell-ILC2 axis that inhibits pancreatic tumor progression.

Giovanni Valenti, Pasquale Laise, Feijing Wu, Ryota Takahashi, Tuo Ruan, Alessandro Vasciaveo, Zhengyu Jiang, Hiroki Kobayashi, Masaki Sunagawa, Moritz Middelhoff and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Giovanni ValentiDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Pasquale LaiseDepartment of Systems Biology, Columbia University, New York, NY, USA; DarwinHealth, Inc., New York, NY, USA.
Feijing WuDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Ryota TakahashiDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Tuo RuanDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Alessandro VasciaveoDepartment of Systems Biology, Columbia University, New York, NY, USA.
Zhengyu JiangDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Hiroki KobayashiDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Masaki SunagawaDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Moritz MiddelhoffKlinik und Poliklinik für Innere Medizin II, Klinikum Rechts der Isar, TU Munich, Munich, Germany.
Henrik NienhüserDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Na FuDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Ermanno MalagolaDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Osmel CompanioniDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
Yoku HayakawaGraduate School of Medicine, Department of Gastroenterology, The University of Tokyo, Tokyo, Japan.
Alina C IugaDepartment of Pathology and Cell Biology, Columbia University, New York, NY, USA.
Andrea CalifanoDepartment of Systems Biology, Columbia University, New York, NY, USA; DarwinHealth, Inc., New York, NY, USA; Chan Zuckerberg Biohub New York, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Biochemistry and Molecular Biophysics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Timothy C WangDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA. Electronic address: tcw21@cumc.columbia.edu.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5M
The Role of Stem Cells and the Microenvironment in Gastrointestinal CancersR35CA210088 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Timothy Cragin Wang · 2017 to 2026
$10.2M
Studying the evolution of drug resistance in prostate cancer at the single cell levelU54CA274506 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DIANA MURRAY · 2023 to 2026
$9.1M
The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2M
Understanding stem cell heterogeneity and niche function in intestinal regeneration after irradiationU01DK103155 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GUHA, CHANDAN, WANG, TIMOTHY CRAGIN · 2014 to 2023
$4.4M
High-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0M
High Performance Computing Cluster for Biomedical ResearchS10OD032433 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2023 to 2023
$2.0M
Gastrin Regulation of Gastric Antral Stem and Corpus Progenitor CellsR01DK128195 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WANG, TIMOTHY CRAGIN · 2021 to 2024
$2.0M
Storage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600k
NCI NIH HHS P30 CA013696NCI NIH HHS R35 CA197745NCI NIH HHS R35 CA210088NCI NIH HHS U54 CA274506NIDDK NIH HHS P30 DK132710NIDDK NIH HHS R01 DK128195NIDDK NIH HHS U01 DK103155NIH HHS S10 OD012351NIH HHS S10 OD021764NIH HHS S10 OD032433
6 · The paper itself

Abstract

Doublecortin-like kinase 1 (Dclk1) expression identifies cells that are rare in normal pancreas but occur with an increased frequency in pancreatic neoplasia. The identity of these cells has been a matter of debate. We employed Dclk1 reporter mouse models and single-cell RNA sequencing (scRNA-seq) to define Dclk1-expressing cells. In normal pancreas, Dclk1 identifies subsets of ductal, islet, and acinar cells. In pancreatic neoplasia, Dclk1 identifies several cell populations, among which acinar-to-ductal metaplasia (ADM)-like cells and tuft-like cells are predominant. These two populations play opposing roles, with Dclk1

Indexed as

Gene Regulatory NetworksIntracellular Signaling Peptides and ProteinsLymphocytesPancreatic NeoplasmsProtein Serine-Threonine KinasesAcinar CellsAnimalsDisease ProgressionDoublecortin-Like KinasesGene Expression Regulation, NeoplasticHumansMiceMice, Inbred C57BLTuft CellsDCLK1 protein, humanDclk1 protein, mouseDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesCP: CancerDclk1ILC2pancreatic neoplasiatuft cell

Identifiers

PMID40408246
PMCPMC12270461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.